Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Decitabine in Elderly AML
NCT00866073Phase 2Completed
- Sponsor
- University Hospital Freiburg
- Start
- Apr 2003
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML), sponsored by University Hospital Freiburg. Primary endpoint: Response Rate (Complete and Partial Remissions, Antileukemic Effect) at 6 months. Started Apr 2003; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00866073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866073.